DWI-High Risk for Peritoneal Carcinomatosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Peritoneal Carcinomatosis+4 MoreWhole-body diffusion-weighted magnetic resonance imaging - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases PM. It has been demonstrated to be superior to CT for patients with known peritoneal disease from colorectal and gynaecological malignancies as a staging tool for cytoreductive surgery. It was also demonstrated to be superior for the detection of PM for gastric cancer patients otherwise considered with a resectable tumor. However, the literature is scarce on the role of DWI/MRI in the detection of peritoneal recurrence for patients with high-risk features, either colorectal cancer (CRC) or appendiceal neoplasms (AN). The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT and diagnostic laparoscopy for detection of PM in the follow-up of patients presenting with CRC or AN and high-risk features for peritoneal recurrence and evaluate how it correlates with intraoperative findings.

Eligible Conditions
  • Peritoneal Carcinomatosis
  • Colorectal Cancer
  • Appendiceal Neoplasm
  • Peritoneal Metastases
  • Appendiceal Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 36 months

24 months
Peritoneal findings
36 months
Early distant recurrence
Early peritoneal recurrence

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

DWI-High Risk
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: DWI-High Risk · No Placebo Group · N/A

DWI-High Risk
DiagnosticTest
Experimental Group · 1 Intervention: Whole-body diffusion-weighted magnetic resonance imaging · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 36 months

Who is running the clinical trial?

Laval UniversityLead Sponsor
391 Previous Clinical Trials
164,918 Total Patients Enrolled
2 Trials studying Peritoneal Carcinomatosis
70 Patients Enrolled for Peritoneal Carcinomatosis
Ciusss de L'Est de l'Île de MontréalOTHER
50 Previous Clinical Trials
3,309 Total Patients Enrolled
1 Trials studying Peritoneal Carcinomatosis
30 Patients Enrolled for Peritoneal Carcinomatosis
Alexandre Brind'Amour, MDPrincipal InvestigatorLaval University
2 Previous Clinical Trials
70 Total Patients Enrolled
2 Trials studying Peritoneal Carcinomatosis
70 Patients Enrolled for Peritoneal Carcinomatosis

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Synchronous peritoneal metastases resected at index surgery.
Synchronous ovarian metastases resected at index surgery.
You have a perforated primary tumor.
You are fit for cytoreductive surgery, if required.
References